ArticleBMC gastroenterology2025
The potential value of serum pepsinogen and gastrin-17 for the diagnosis of chronic atrophic gastritis at different stages of severity: a clinical diagnostic study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Pepsinogen Assay Findings in Individuals With Gastric Atrophy and Intestinal Metaplasia.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Effect of sucralfate suspension gel on gastroscopic pathology and inflammatory cytokines in patients with Helicobacter pylori-positive chronic non-atrophic gastritis.Pakistan journal of medical sciences · 2026Article
- Differential impacts of Helicobacter pylori antibody typing on gastric secretory function: a cross-sectional study based on serum biomarkers.BMC gastroenterology · 2026Observational
- VTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION.Arquivos de gastroenterologia · 2026Article
- Machine learning models using serum gastric biomarkers for the non-invasive prediction of atrophic gastritis: a comparative study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPepsinogen (PG) and gastrin-17 (G-17) are crucial in the gastric digestive processes. This study aimed to assess the diagnostic value of the serum PG and G-17 in identifying chronic atrophic gastritis (CAG) at different stages of severity under varying Helicobacter pylori (H. pylori) infection statuses.
methodsWe enrolled 300 participants from August 2023 to May 2024. All participants underwent gastroscopy with biopsy, and blood samples were taken for pepsinogen I (PGI), pepsinogen II (PGII), G-17, and H. pylori tests. The differences in G-17 and PG-related parameters were analyzed across groups, taking H. pylori infection status into account. The diagnostic performance of these markers was then evaluated both individually and in combination to distinguish CAG stages of severity. Statistical analysis was performed using SPSS statistical software.
resultsAccording to pathological results, patients were divided into the non-atrophic gastritis group (NAG, n = 179), the mild atrophic gastritis group (MAG, n = 62), and the moderate and severe atrophic gastritis group (MSAG, n = 59). In the same pathological groups (NAG, MAG, and MSAG), PGII levels were higher in the H. pylori-positive subgroup, while the PGI/PGII ratio (PGR) was lower (p < 0.05). Serum PGII and G-17 levels increased with the pathological severity of the mucosa (p < 0.001, r = 0.364 and p < 0.001, r = 0.304, respectively), while PGR levels decreased with mucosal deterioration (p < 0.001, r = -0.407). Combination of PGI, PGII, PGR, and G-17 showed an area under the curve (AUC) of 0.723 (95% CI: 0.662-0.784), with a sensitivity of 65.29% and a specificity of 73.18% for detecting the presence of any CAG. For progressive CAG, which was defined by MSAG and classified into stages II-IV according to the Operative Link on Gastritis Assessment (OLGA) system, the AUC was 0.759 (95% CI: 0.683-0.836), with a sensitivity of 66.10% and a specificity of 83.40%, demonstrating the potential for even higher diagnostic ability. Among all the H. pylori-positive cohorts, PGII exhibited a higher AUC compared to the combined diagnostic approach using PGI, PGII, PGR, and G-17 (CAG: 0.656 vs. 0.654, MAG: 0.589 vs. 0.571, MSAG: 0.707 vs. 0.706, respectively).
conclusionSerum PG and G-17 show potential in identifying CAG and MSAG. However, their diagnostic accuracy for MAG remains limited and would be better used as adjunctive indicators in conjunction with endoscopic examination. Further validation in larger, multi-center studies is needed to assess their utility in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.